Investigation of Effective Drugs in the Treatment of Patients with COVID-19

Esmaeil Mehraeen; Shaghayegh Kianzad; Niloufar Gharavi; Mohammad Heydari; Amirali Karimi; Vahideh Aghamohammadi; Mohammad Mehrtak; Amirhossein  Behzad; Mohammad   Ezzati; Khadijeh  Nasiri; SeyedAhmad  SeyedAlinaghi; Ali  Asadollahi-Amin; Omid  Dadras

doi:10.18502/jimc.v6i2.12240

Esmaeil Mehraeen Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran
Shaghayegh Kianzad School of Medicine, Iran University of Medical Sciences, Tehran ,Iran
Niloufar Gharavi School of Medicine, Iran University of Medical Sciences, Tehran ,Iran
Mohammad Heydari Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran
Amirali Karimi School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Vahideh Aghamohammadi Department of Nutrition, Khalkhal University of Medical Sciences, Khalkhal, Iran
Mohammad Mehrtak School of Medicine and Allied Medical Sciences, Ardabil University of Medical Sciences, Ardabil, Iran
Amirhossein Behzad Department of Nursing, Khalkhal University of Medical Sciences, Khalkhal, Iran
Mohammad Ezzati Department of Nursing, Khalkhal University of Medical Sciences, Khalkhal, Iran
Khadijeh Nasiri Department of Nursing, Khalkhal University of Medical Sciences, Khalkhal, Iran
SeyedAhmad SeyedAlinaghi Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Ali Asadollahi-Amin Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Omid Dadras Section Global Health and Rehabilitation, Western Norway University and Applied Sciences, Norway

DOI: https://doi.org/10.18502/jimc.v6i2.12240

Keywords: COVID-19, Drugs, Medicine, Treatment, SARS-CoV-2

Abstract

Background: Due to the lack of definitive treatments for corona disease and the use of various medications in protocols around the world, it is necessary to conduct more epidemiological studies exploring the effect of different available therapeutic regimes; therefore, the present study aimed to explore the current effective drugs for the treatment of hospitalized COVID-19 patients.

Methods: The present study is a descriptive-analytical study that was conducted between August and September of 2021 at Khalkhal University of Medical Sciences. A convenient sampling method was employed to retrieve the data from the available hospital records, including 252 documents from COVID-19 hospitalized patients. A researcher-made checklist was used to record the data. Data were analyzed using SPSS 26 software.

Results: The findings showed that Hypertension and Hypotension (n=47,18.7%) are the most common underlying diseases in the study sample. The most therapeutic regimen was the combination of Remdesivir and Dexametason (n=137,54.4%) in hospitalized COVID-19 patients. There are a variety of organ involvements and presentations to the COVID-19; however, most patients experience a mild-to-moderate, self-limited disease; even though, the disease could progress to more fatal cases and lead to death.

Conclusion: The main pathology exists in the lungs which are caused by an inappropriate immune response that leads to a severe inflammatory response. Therefore, antiviral and anti-inflammatory drugs are currently the first-line therapy for hospitalized patients.